Advertisement
UK markets close in 4 hours 11 minutes
  • FTSE 100

    8,117.81
    +38.95 (+0.48%)
     
  • FTSE 250

    19,815.75
    +213.77 (+1.09%)
     
  • AIM

    755.53
    +2.41 (+0.32%)
     
  • GBP/EUR

    1.1661
    +0.0004 (+0.04%)
     
  • GBP/USD

    1.2518
    +0.0007 (+0.06%)
     
  • Bitcoin GBP

    51,269.54
    +365.86 (+0.72%)
     
  • CMC Crypto 200

    1,383.80
    -12.74 (-0.91%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     
  • GOLD FUTURES

    2,359.60
    +17.10 (+0.73%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,058.02
    +140.74 (+0.79%)
     
  • CAC 40

    8,042.41
    +25.76 (+0.32%)
     

A Overview of Merck’s Diabetes Products in 1Q18

A Overview of Merck’s Diabetes Products in 1Q18

Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.